CoChat
Sign Up
Cited by 294Parkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatmentsDeep Brain Stimulation and Movement Disorders

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

Open access
Boxer, Adam L, Lang, Anthony E, Grossman, Murray, Knopman, David S, Miller, Bruce L, Schneider, Lon S, Doody, Rachelle S, Lees, Andrew, Golbe, Lawrence I, Williams, David R, Corvol, Jean-Cristophe, Ludolph, Albert, Burn, David, Lorenzl, Stefan, Litvan, Irene, Roberson, Erik D, Höglinger, Günter U, Koestler, Mary, Jack, Clifford R, Van Deerlin, Viviana, Randolph, Christopher, Lobach, Iryna V, Heuer, Hilary W, Gozes, Illana, Parker, Lesley, Whitaker, Steve, Hirman, Joe, Stewart, Alistair J, Gold, Michael, Morimoto, Bruce H·2014·The Lancet Neurology
DOI 10.1016/s1474-4422(14)70088-2PMC PMC4129545
Open this paper in CoChat — free account

Abstract

Background In preclinical studies, davunetide promoted microtubule stability and reduced tau phosphorylation. Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP. We assessed the safety and efficacy of davunetide in patients with PSP.Methods In a double-blind, parallel group, phase 2/3 trial, participants were randomly assigned with permuted blocks in a 1:1 ratio to davunetide (30 mg twice daily, intranasally) or placebo for 52 weeks at 48 centres in Australia, Canada, France, Germany, the UK, and the USA. Participants met the modified Neuroprotection and Natural History in Parkinson Plus Syndrome study criteria for PSP. Primary endpoints were the change from baseline in PSP Rating Scale (PSPRS) and Schwab and England Activities of Daily Living (SEADL) scale at up to 52 weeks. All participants and study personnel were masked to treatment assignment. Analysis was by intention to treat. The trial is registered with Clinicaltrials.gov, number NCT01110720.Findings 313 participants were randomly assigned to davunetide (n=157) or to placebo (n=156), and 241 (77%) completed the study (118 and 156 in the davunetide and placebo groups, respectively). There were no differences in the davunetide and placebo groups in the baseline PSPRS and SEADL. The davunetide and placebo groups did not differ in the change from baseline in PSPRS (median 11·8 [95% CI 10·5 to 13·0] vs 11·8 [10·5 to 13·0], respectively, p=0·41) or SEADL (-0·20 [-0·20 to -0·17] vs -0·20 [-0·22 to -0·17], respectively, p=0·92). 54 serious adverse events were reported in each of the treatment groups, including 11 deaths in the davunetide group and ten in the placebo group. The frequency of nasal adverse events was greater in the davunetide group than in the placebo group (epistaxis 18 [12%] of 156 vs 13 [8%] of 156, rhinorrhoea 15 [10%] vs eight [5%], and nasal discomfort 15 [10%] vs one [<1%]).Interpretation Davunetide is not an effective treatment for PSP. Clinical trials of disease-modifying treatment are feasible in patients with PSP and should be pursued with other promising tau-directed treatments.Funding Allon Therapeutics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(14)70088-2

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

Sorted by citations

Items 101–200 of 294

Related

See all

Metadata

Authors
Boxer, A. L., Lang, A. E., Grossman, M., Knopman, D. S., Miller, B. L., Schneider, L. S., Doody, R. S., Lees, A., Golbe, L. I., Williams, D. R., Corvol, J.-C., Ludolph, A., Burn, D., Lorenzl, S., Litvan, I., Roberson, E. D., Höglinger, G. U., Koestler, M., Jack, C. R., Van Deerlin, V., Randolph, C., Lobach, I. V., Heuer, H. W., Gozes, I., Parker, L., Whitaker, S., Hirman, J., Stewart, A. J., Gold, M., & Morimoto, B. H.
Affiliations
  • University of California, San Francisco (US)
  • University of Toronto (CA)
  • University of Pennsylvania (US)
  • Mayo Clinic (US)
  • University of Southern California (US)
  • Baylor College of Medicine (US)
  • UCL Queen Square Institute of Neurology (GB)
  • Rutgers, The State University of New Jersey (US)
  • Monash University (AU)
  • University Hospital Ulm (DE)
  • Newcastle University (GB)
  • LMU Klinikum (DE)
  • University of California San Diego (US)
  • University of Alabama at Birmingham (US)
  • Technical University of Munich (DE)
  • Loyola University Chicago (US)
  • Tel Aviv University (IL)
  • Arbutus Biopharma (Canada) (CA)
  • Omeros Corporation (United States) (US)
  • Paladin Labs (Canada) (CA)
  • Celerion (United States) (US)
Corresponding author
Boxer, Adam L
ORCID
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2014-07
Volume
13
Issue
7
Pages
676-685
ISSN
1474-4422 (ISSN-L)
DOI
10.1016/s1474-4422(14)70088-2
PMC
PMC4129545
OpenAlex
W2129669150
Cited by
294
References
43
Citations by year
2026: 21 · 2025: 18 · 2024: 15 · 2023: 22 · 2022: 16 · 2021: 25 · 2020: 27 · 2019: 33 · 2018: 23 · 2017: 27 · 2016: 36 · 2015: 20 · 2014: 10
FWCI
20.20
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
Allos Therapeutics
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
Keywords
davunetide, progressive supranuclear palsy, tau pathology, microtubule stabilization, tau phosphorylation, intranasal drug delivery, neuroprotection, PSP Rating Scale, activities of daily living, drug safety, epistaxis, serious adverse events, atypical parkinsonism, disease-modifying therapy
MeSH terms
Aged, Double-Blind Method, Female, Humans, Male, Oligopeptides, Supranuclear Palsy, Progressive, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review